![6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds](/docs/US/2020-08-11/US10738063B2/abs.jpg.600x600.jpg)
- Patent Title: 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
-
Application No.: US16427627Application Date: 2019-05-31
-
Publication No.: US10738063B2Publication Date: 2020-08-11
- Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Patrick Robert Verhoest , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Travis T. Wager , Matthew Merrill Hayward
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agency: Haley Guiliano LLP
- Agent James F. Haley, Jr.
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D519/00
![6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds](/abs-image/US/2020/08/11/US10738063B2/abs.jpg.150x150.jpg)
Abstract:
The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
Public/Granted literature
- US20190300546A1 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE COMPOUNDS Public/Granted day:2019-10-03
Information query
